Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has received a consensus recommendation of "Hold" from the nine analysts that are currently covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $8.24.

A number of equities research analysts have issued reports on ZNTL shares. HC Wainwright decreased their price target on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a "buy" rating for the company in a report on Wednesday, January 29th. Guggenheim dropped their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, November 15th. UBS Group cut their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Wells Fargo & Company reduced their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 30th. Finally, Wedbush reaffirmed a "neutral" rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th.

Insiders Place Their Bets

In other news, Director Jan Skvarka acquired 60,000 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the acquisition, the director now owns 149,551 shares in the company, valued at $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Ingmar Bruns bought 20,000 shares of the stock in a transaction on Thursday, February 6th. The stock was purchased at an average cost of $2.28 per share, with a total value of $45,600.00. Following the purchase, the insider now directly owns 36,629 shares of the company's stock, valued at approximately $83,514.12. This represents a 120.27 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company's stock.

Institutional Trading of Zentalis Pharmaceuticals

Large investors have recently made changes to their positions in the company. Barclays PLC grew its stake in Zentalis Pharmaceuticals by 18.5% in the third quarter. Barclays PLC now owns 75,395 shares of the company's stock valued at $277,000 after acquiring an additional 11,748 shares during the period. GSA Capital Partners LLP increased its stake in Zentalis Pharmaceuticals by 138.5% during the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company's stock worth $2,240,000 after purchasing an additional 353,384 shares in the last quarter. Verition Fund Management LLC raised its holdings in Zentalis Pharmaceuticals by 172.1% during the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company's stock worth $5,536,000 after buying an additional 951,500 shares during the period. Primecap Management Co. CA lifted its stake in Zentalis Pharmaceuticals by 21.6% in the third quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company's stock valued at $5,513,000 after buying an additional 265,690 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Zentalis Pharmaceuticals by 115.6% during the fourth quarter. SG Americas Securities LLC now owns 56,389 shares of the company's stock worth $171,000 after acquiring an additional 30,240 shares in the last quarter.

Zentalis Pharmaceuticals Stock Performance

Shares of Zentalis Pharmaceuticals stock remained flat at $2.43 during trading on Wednesday. The stock had a trading volume of 849,132 shares, compared to its average volume of 3,195,366. The company has a market capitalization of $173.16 million, a PE ratio of -0.98 and a beta of 1.81. Zentalis Pharmaceuticals has a fifty-two week low of $1.61 and a fifty-two week high of $18.07. The business's fifty day moving average is $2.65 and its two-hundred day moving average is $3.12.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.36. As a group, analysts forecast that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.